Literature DB >> 11440030

Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.

H Wu1, A Dimitrakopoulou-Strauss, T O Heichel, B Lehner, L Bernd, V Ewerbeck, C Burger, L G Strauss.   

Abstract

This study was carried out to evaluate bone lesions using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) and to explore whether dynamic and quantitative PET data may help to differentiate benign lesions from malignant masses. Forty patients with primary bone lesions were studied. The final diagnosis was confirmed by histopathology. A 60-min dynamic FDG PET acquisition was undertaken in all subjects. From the dynamic PET images, indices such as the average and maximal standardised uptake values (SUVs), the tumour SUV-to-muscle SUV ratio (T/M) and the SUV at 60 min-to-SUV at 30 min ratio (averSUV60/30 min and maxSUV60/30 min) were produced. Patlak graphical analysis was used to obtain the influx constant (Ki), and the metabolic rate of FDG (MRFDG) was calculated. Based on the receiver operator characteristic curve, the sensitivity and specificity for each parameter in differentiating between malignant and benign lesions were evaluated. The histological results revealed 21 malignant tumours and 19 benign lesions in this group. The MRFDG and SUV indices in malignant lesions were significantly higher than those in benign lesions. However, each index showed a considerable overlap between benign and malignant lesions. Average SUV correlated positively with MRFDG (r=0.67). When a cut-off of 1.8 average SUV was used, the sensitivity and specificity for discrimination of malignancy from benign disease were 85% and 82.4%, respectively. MRFDG showed a similar sensitivity (82.4%) and a better specificity (92.9%). A combination consisting of a cut-off of average SUV (1.8) and averSUV60/30 min (1.1) resulted in an improvement of specificity to 93.3%, with a small reduction in sensitivity (81.3%) as compared with exclusive use of SUV. The results of this study indicate that a detectable difference in glucose metabolism exists between malignant and benign skeletal lesions. The static FDG uptake indices alone may not enable adequate differentiation between benign and malignant lesions. Quantitative dynamic imaging may provide more helpful information, but will not permit a definite diagnosis. The use of uptake indices may represent an alternative and interesting approach to the evaluation of bone lesions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11440030     DOI: 10.1007/s002590100511

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

1.  Has PET become an important clinical tool in paediatric imaging?

Authors:  Klaus Hahn; Thomas Pfluger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

Review 2.  Use of positron emission tomography in anticancer drug development.

Authors:  Eric O Aboagye; Patricia M Price
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

3.  68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Authors:  Christos Sachpekidis; Leyun Pan; Boris A Hadaschik; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

Review 4.  (18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications.

Authors:  Gianpiero Manca; Eleonora Vanzi; Domenico Rubello; Francesco Giammarile; Gaia Grassetto; Ka Kit Wong; Alan C Perkins; Patrick M Colletti; Duccio Volterrani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-19       Impact factor: 9.236

5.  Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Authors:  D-S Shin; O-J Shon; S-J Byun; J-H Choi; K-A Chun; I-H Cho
Journal:  Skeletal Radiol       Date:  2008-02-29       Impact factor: 2.199

6.  Glucose corrected standardized uptake value (SUVgluc) in the evaluation of brain lesions with 18F-FDG PET.

Authors:  Asae Nozawa; Ali Hosseini Rivandi; Santosh Kesari; Carl K Hoh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-10       Impact factor: 9.236

7.  A study of non-invasive Patlak quantification for whole-body dynamic FDG-PET studies of mice.

Authors:  Xiujuan Zheng; Lingfeng Wen; Shu-Jung Yu; Sung-Cheng Huang; David Dagan Feng
Journal:  Biomed Signal Process Control       Date:  2012-09-01       Impact factor: 3.880

8.  Total-Body Quantitative Parametric Imaging of Early Kinetics of 18F-FDG.

Authors:  Tao Feng; Yizhang Zhao; Hongcheng Shi; Hongdi Li; Xuezhu Zhang; Guobao Wang; Patricia M Price; Ramsey D Badawi; Simon R Cherry; Terry Jones
Journal:  J Nucl Med       Date:  2020-09-18       Impact factor: 10.057

9.  Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.

Authors:  Asae Nozawa; Ali Hosseini Rivandi; Masayuki Kanematsu; Hiroaki Hoshi; David Piccioni; Santosh Kesari; Carl K Hoh
Journal:  Nucl Med Commun       Date:  2015-06       Impact factor: 1.690

10.  The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.

Authors:  Mustafa Takesh
Journal:  ISRN Oncol       Date:  2012-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.